key: cord-0683904-fd5rr87z
authors: Yuan, Shuofeng; Chan, Jasper F.W.; Chik, Kenn K.H.; Chan, Chris C.Y.; Tsang, Jessica O.L.; Liang, Ronghui; Cao, Jianli; Tang, Kaiming; Chen, Lin-Lei; Wen, Kun; Cai, Jian-Piao; Ye, Zi-Wei; Lu, Gang; Chu, Hin; Jin, Dong-Yan; Yuen, Kwok-Yung
title: Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
date: 2020-05-28
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104960
sha: 9ad519eab4388637307c920a1d88a4941bde6a60
doc_id: 683904
cord_uid: fd5rr87z

Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5-10% depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50% maximal effective concentrations (EC(50)) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals, we established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC(50) 1.13-2.01µM). Bexarotene demonstrated the highest Cmax:EC(50) ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and ivermectin. These results demonstrated the efficacy of the two-tier screening system and identified potential COVID-19 treatments which can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.

Coronaviruses are positive sense, single stranded, enveloped RNA viruses that have repeatedly crossed species barriers to cause disease in human and animals [1] . In the past two [2] [3] [4] . Within just 4 months, the number of patients with SARS-CoV-2 infection, or Coronavirus Disease 2019 (COVID- 19) , has exceeded the total number of cases of SARS and MERS by nearly 100 times, with more than 1.2 million confirmed cases and over 60,000 deaths globally [5] . The clinical severity of COVID-19 ranges from asymptomatic infection to fatal disease. The disease is usually mild in children, but severe infection in immunocompromised and elderly patients may be associated with a crude case fatality rate of about 15% [6] [7] [8] . Patient with severe COVID-19 may develop acute respiratory distress syndrome, multiorgan dysfunction syndrome, and other extrapulmonary manifestations such as lymphopenia, diarrhea, confusion, deranged liver and renal function tests, and elevated D-dimer, fibrinogen, lactate dehydrogenase, and inflammatory marker levels [9, 10] . A major reason for the poor clinical outcome of COVID-19 patients and difficulty in controlling the expansion of the pandemic is the lack of effective vaccine or antiviral for treatment and prophylaxis.

Similar to other emerging viral infections, the de novo development of antiviral drugs would inevitably lag behind the rapid progression of the epidemic [11] . Drug repurposing is therefore a feasible strategy to quickly identify clinically approved drugs with known pharmacological properties and safety profiles that can be immediately used in clinical trial settings. A number of existing drugs, such as remedsivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, have been reported to exhibit anti-SARS-CoV-2 activity in vitro and/or in a very small number of patients [12] [13] [14] [15] . Remdesivir is a nucleotide analogue with broad-spectrum antiviral activities including against SARS-CoV-2 [12] . Chloroquine and hydroxychloroquine are mildly immunosuppressive drugs used in the treatment of autoimmune diseases and malaria that exhibited 50% maximal effective concentration (EC50) at or above the J o u r n a l P r e -p r o o f peak serum concentration (Cmax) achievable with standard dosing in human [12, 16] . A recent non-randomized small-scale clinical study showed that hydroxychloroquine with or without azithromycin significantly reduced the viral load and duration of virus shedding in 20 COVID-19 patients [13] . Nafamostat and camostat are a serine protease inhibitor used in the treatment of chronic pancreatitis and reflux esophagitis [14] . Ivermectin is a macrocyclic lactone used in the treatment of various parasitic infections [15] . However, data from well-designed randomized controlled trials for these drugs are not yet available. Therefore, there is an urgent need to search for additional drug compounds with anti-SARS-CoV-2 activity among clinically approved drugs.

In this study, we first established a robust two-tier drug screening system by combining SARS-CoV-2 enzyme-linked immunosorbent assay with cell viability assay, and then applied it to screen an FDA-approved drug compound library. We successfully identified a number of drug compounds with anti-SARS-CoV-2 activity, including bexarotene which has broad-spectrum anti-coronaviral activity and a higher Cmax to EC50 ratio than most other reported potential anti-SARS-CoV-2 agents.

VeroE6 (ATCC® CRL-1586™) and Caco2 cells (ATCC® HTB-37™) were purchased from ATCC and maintained in Dulbecco's modified eagle medium (DMEM, Gibco, CA, USA) culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco), 50 U/mL penicillin, and 50 µg/mL streptomycin as previously described [17] . All experiments involving live SARS-CoV-2 and MERS-CoV followed the approved standard operating procedures of the Biosafety Level 3 facility at the Department of Microbiology, The University of Hong Kong, as previously described [19, 20] . The FDA-approved drug library (Cat# HY-L022) and all the tested drug compounds were purchased from MedChem Express (Monmouth Junction, NJ, USA).

The CellTiterGlo® luminescent assay (Promega Corporation, Madison, WI, USA) was performed to detect the cytotoxicity of the selected drug compounds as previously described [21] .

Briefly, VeroE6 cells (4×10 4 cells/well) were incubated with different concentrations of the individual compound for 48h, followed by the addition of substrate and measurement of luminance 10 min later. The CC50 of the drug compounds were calculated by Sigma plot (SPSS) in an Excel add-in ED50V10. The CPE inhibition assay was performed as previously described with slight modifications to evaluate the individual drug compounds' cell protection effects against SARS-CoV-2 infection [21] . Briefly, VeroE6 cells seeded in 96-well plates were infected with SARS-CoV-2 for 1 h with 0.01 multiplicity of infection (MOI), followed by washing with phosphate-buffered saline (PBS) and replacement of fresh DMEM medium containing serially diluted drug compounds and 0.1% DMSO as negative control. The cell viability of each well was determined at 3 days post-infection (dpi) by the CellTiterGlo® luminescent assay. ELISA was performed to determine the amount of viral N protein expression in the culture supernatant of SARS-CoV-2-infected cells using a similar approach as previously described [22] .

Briefly, 500 ng/well of mouse-anti-SARS-CoV-N monoclonal antibody (clone 14E7A11A8) was coated in 96-well ELISA plates for overnight incubation at 4°C, followed by blocking with 2.5% 

To identify anti-SARS-CoV-2 inhibitors, confluent VeroE6 cells in 96-well culture plates (4×10 4 cells/well) in triplicates were infected with SARS-CoV-2 at 0.004 MOI. One hour after virus adsorption, the inoculum was removed and then drug-containing medium (10µM) was added.

Next, after 72h, 20µl of cell culture supernatant was diluted into 80µl of PBS before adding to the antibody-coated ELISA plate for SARS-CoV-2-N detection, while another 20µl/well of J o u r n a l P r e -p r o o f CellTiterGlo® substrate was added to the original cell culture plates for cell viability evaluation by CPE inhibition assay.

Viral load reduction assay was performed on VeroE6 and Caco2 cells, as described previously with modifications [24, 25] J o u r n a l P r e -p r o o f

Plaque reduction assay was performed to plot the 50% antiviral effective dose (EC50) as we previously described with slight modifications [24, 27] . Briefly, VeroE6 cells were seeded at 4×10 5 cells/well in 12-well tissue culture plates on the day before carrying out the assay. After After removal of the agarose plugs, the monolayers were stained with 0.7% crystal violet (BDH, Merck) and the plaques counted. The percentage of plaque inhibition relative to the control (i.e.

without the addition of compound) wells were determined for each drug compound concentration.

The EC50 was calculated using Sigma plot (SPSS) in an Excel add-in ED50V10. The plaque reduction assay experiments were performed in triplicate and repeated twice for confirmation.

Time-of-drug-addition assay was performed for the selected compound as previously described with slight modifications [25] . Briefly, VeroE6 cells were seeded in 24-well plates ( 

Antigen expression in SARS-CoV-2-infected cells was detected with an in-house rabbit antiserum against SARS-CoV-N protein, which cross-reacted with the SARS-CoV-2-N protein due to their high amino acid homologies [17, 23] . 

To develop a drug screening system for SARS-CoV-2, we first characterized the viral replication (Fig. 1C) . Regardless of the MOI, the viral RNA load plateaued at 48hpi. The viral N protein expression followed a delayed but similar pattern as that of the viral RNA load, with the peak viral antigen expression being observed at 72hpi (Fig. 1D ).

The signal window is determined by the upper and lower boundaries of the assay readout and is considered a major parameter for the overall assay quality measurement. The qRT-PCR assay exhibited the highest signal window (~4 log difference between SARS-CoV-2-infected and noninfected samples) but was laborious, and was thus inefficient as a high-throughput drug compound screening assay. On the other hand, the ELISA (~6 folds) and cell viability assay (~4 folds) also exhibited reasonably high signal differences between infected cells and baseline at 72hpi and provided a wide signal window. Therefore, we exploited the combination of ELISA and cell viability assay as a two-tier drug screening system for finding potential SARS-CoV-2

antivirals. This combinational screening system is rapid, non-labor-intensive, and can easily exclude false-positive results due to cytotoxicity. Using this newly established system, we screened an FDA-approved drug library containing 1528 drug compounds under the optimized conditions of 0.004 MOI at 72hpi with each drug concentration fixed at 10µM. At 72hpi, 20µl/well of cell culture supernatant was harvested for SARS-CoV-2-N detection before addition of another 40µl/well CellTiter-Glo® substrate for determination of cell viability (Fig. 2) . Among the 1528 drug compounds, we identified 34 primary hit drug compounds with ≥4-fold reduction of detection signal in ELISA. In the secondary screen by cell viability assay, 19 of these 34 drug compounds showed <10% CPE at 72hpi (Table 1) . Notably, hydroxychloroquine, nafamostat, and ivermectin which were previously shown to exhibit anti-SARS-CoV-2 activity were also identified in our primary screen with ELISA, but they showed >10% CPE at 72hpi and were therefore excluded from the 19 drug compound list. Camostat was not detected in the primary screen but this might be related to its EC50 being higher than 10µM which was used in our primary screen. Remdesivir was not included in the library and was therefore not identified.

Next, these 19 primary hit drug compounds were subjected to viral load reduction assay for prioritization based on their dose-dependent anti-SARS-CoV-2 effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene were identified as the most potent anti-SARS-CoV-2 drug compounds using the cut-off of 90% effective concentrations (EC90) <10µM after treating VeroE6 cells with 0.01 MOI of SARS-CoV-2 for 48h. Using plaque reduction assay, the EC50 of the drug compounds were determined to be J o u r n a l P r e -p r o o f 1.13µM (cetilistat), 1.38µM (diiodohydroxyquinoline), 1.94µM (abiraterone acetate), and 2.01µM (bexarotene) (Fig. 3A to 3D ). At 48hpi, the 50% cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene were >100µM, >100µM, 92.35µM, and 38.21µM, respectively ( Table 2 ). The selectivity index of these four drug compounds were >88.50 (cetilistat), >72.46 (diiodohydroxyquinoline), 47.60 (abiraterone acetate), and 19.01 (bexarotene), respectively.

To more clearly demonstrate the anti-SARS-CoV-2 activities of these four identified drug compounds, we included remdesivir as a comparator drug. Similar to remdesivir, treatment with any one of the four drug compounds below the non-toxic drug concentration of 10µM, markedly suppressed SARS-CoV-2-N protein expression (Fig. 4) . As shown in Fig. 5A , all four drug compounds exhibited dose-dependent viral load reduction with magnitudes of 1 log to 3 logs. At 10µM of drug concentration, treatment with cetilistat exhibited about 3 logs reduction at 48hpi, as comparable level achieved by remdesivir which demonstrated an EC50 of 1.04µM in our study.

Caco2 (human colorectal adenocarcinoma) cell culture supernatants and cell lysates (Fig. 5B ). In addition to viral load reduction, treatment with any one of these four drug compounds provided cell protection effects. In the CPE inhibition assay, treatment with 10µM of cetilistat completely inhibited CPE development in VeroE6 cells at 72hpi, while diiodohydroxyquinoline, abiraterone acetate, and bexarotene achieved up to ~70% CPE inhibition (Fig. 5C) . Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene inhibited the viral load, viral antigen expression, and infectious viral particle production of SARS-CoV-2, and protected SARS-CoV-2-induced cell damages at comparable levels of remdesivir.

To investigate which steps of the SARS-CoV-2 replication cycle were interrupted by the selected drug compounds, we performed a time-of-drug-addition assay by treating virus-infected VeroE6 cells to each drug compound at different time points, followed by viral titer measurements at 9

hpi, when the first round of progeny virions were detectable in the cell culture supernatant.

VeroE6 cells were infected by 0.500 MOI of SARS-CoV-2, before and after which four different treatments were carried out (Fig. 6A) . Addition of cetilistat, diiodohydroxyquinoline, or abiraterone acetate at 0 hpi and 3 hpi, but not pre-treatment with host cells or during virus adsorption (co-infection) significantly reduced viral replication, suggesting that these three drug compounds disrupted the post-entry events of the SARS-CoV-2 replication cycle (Fig. 6B ). In contrast, bexarotene was only effective when co-infected with cells, suggesting that it interfered with virus entry either by blocking the host ACE2 receptor or the viral components required for cell attachment and entry. To further delineate the step of SARS-CoV-2 entry that is affected by bexarotene, VeroE6 cells were placed at 4 o C for 2 hours which only permitted virus attachment to the cell surface and then at 37 o C for 1 hour which enabled virus internalization (Fig. 6C ). As shown in Fig. 6D , bexarotene did not block virus-host receptor binding, but significantly reduced viral load during virus internationalization. These results suggested that bexarotene interfered with SARS-CoV-2 internalization without blocking its binding to the host cell surface.

Interestingly, bexarotene also demonstrated antiviral activity against the highly virulent MERS-CoV (EC50 of 2.12 µM), suggesting that it has the potential of being a "pan-coronavirus" antiviral ( Fig. 6E ).

The newly established two-tier screening system in this study was robust and able to identify other drug compounds that were shown to exhibit anti-SARS-CoV-2 activity, including chloroquine, hydroxychloroquine, ivermectin, and nafamostat. This allowed us to rapidly and systematically screen a drug library consisting 1528 FDA-approved drug compounds and identify four drug compounds that showed anit-SARS-CoV-2 activities at low micromolar concentrations (EC50 = 1.13 to 2.01). Cetilistat is a pancreatic lipase inhibitor that blocks fat digestion and absorption used in the treatment of obesity [28] . Diiodohydroxylquinoline, also known as uidoquinol, is a quinolone derivative that is used as a luminal amebicide for the treatment of amoebiasis [29] . Cetilistat is rapidly hydrolyzed into its metabolites in the presence of bile and diiodohydroxylquinoline is poorly absorbed into circulatory system [28, 30] .

Importantly, about 15-20% of COVID-19 patients develop gastrointestinal symptoms with some also having detectable viral RNA and even infectious virus particles [31] . In a SARS-CoV-2infected hamster model, it was found that the animals' intestines exhibited severe inflammation with detectable viral RNA and abundant viral nucleocapsid protein expression [23] . These findings showed that like in SARS, feces might also be a potential source of infection in COVID-19 [2, 32] . Thus, besides being administered by inhalation, oral cetilisat and diiodohydroxylquinoline might have a role as topical luminal antivirals to reduce viral shedding in the gastrointestinal tract.

Both abiraterone acetate and bexarotene are non-chemotherapeutic antineoplastic drugs with limited immunosuppressive effects. Abiraterone acetate is used in combination with corticosteroid to treat refractory prostate cancer through androgen deprivation by inhibition of J o u r n a l P r e -p r o o f the androgen synthesizing enzyme CYP17A1 [33, 34] . Bexarotene is a third-generation retinoid used in the treatment of cutaneous T cell lymphoma, non-small cell lung cancer, and breast cancer [35] [36] [37] [38] . We showed that abiraterone acetate and bexarotene potently inhibited SARS-CoV-2 replication in vitro with EC50 of 1.94 μM and 2.01μM, respectively. Of particular interest is bexarotene which has a peak serum concentration (Cmax) of 3.39μM after an oral dose of 300mg/m 2 [39] . The Cmax to EC50 ratio of bexarotene for SARS-CoV-2 (1.69) is higher than those achieved with standard dosing of chloroquine, hydroxychloroquine, and ivermectin (0.02 to 1.04). Moreover, the time required to achieve Cmax (Tmax) with standard oral dosing of bexarotene is short (2.5 hours), which is important especially in COVID-19 patients who are acutely ill with rapid clinical deterioration [39] . We have previously shown that AM580 and tamibarotene, which belong to the same drug class as bexarotene, exhibited broad-spectrum antiviral activities against coronaviruses (MERS-CoV and SARS-CoV), influenza viruses, enterovirus A71, Zika virus, and adenovirus [21] . We therefore additionally tested the antiviral activity of bexarotene against the highly virulent MERS-CoV, and showed that it indeed also inhibited MERS-CoV with an EC50 of 2.12 µM. The potential of bexarotene and its related analogue compounds as "pan-coronavirus" agents should be further evaluated in suitable animal models for COVID-19 and other human-pathogenic coronaviruses.

In conclusion, the robust two-tier drug compound screening system established in this study represented a novel platform for conducting drug discovery programmes for COVID-19. indicates the highest drug concentration tested in the cytotoxicity assay was 100µM.

Abbreviations: CC50, 50% cytotoxic concentration; EC50, 50% maximal effective concentration;

EC90, 90% maximal effective concentration.

Interspecies transmission and emergence of novel viruses: lessons from bats and birds

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

A Novel Coronavirus from Patients with Pneumonia in China

World Health Organization (2020) Coronavirus disease 2019 (COVID-19) Situation Report -77

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Coronaviruses -drug discovery and therapeutic options

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

An observational study on the comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target

Antigenic cross-reactivity between severe acute respiratory syndromeassociated coronavirus and human coronaviruses 229E and OC43

COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens

A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication

Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers

The treatment of amoebiasis with diodoquin

Cetilistat, a new lipase inhibitor for the treatment of obesity

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and metaanalysis

In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase

Inter-and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells

The optimal use of bexarotene in cutaneous T-cell lymphoma

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer

Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

This study was partly supported by funding from Health@InnoHK (Centre for Virology,